346 related articles for article (PubMed ID: 19588139)
1. Intestinal perforation associated with rituximab therapy for post-transplant lymphoproliferative disorder after liver transplantation.
Cornejo A; Bohnenblust M; Harris C; Abrahamian GA
Cancer Chemother Pharmacol; 2009 Sep; 64(4):857-60. PubMed ID: 19588139
[TBL] [Abstract][Full Text] [Related]
2. Successful prolonged rituximab treatment for post-transplant lymphoproliferative disorder following living donor liver transplantation in a child.
Hayashida M; Ogita K; Matsuura T; Takahashi Y; Nishimoto Y; Ohga S; Hara T; Soejima Y; Taketomi A; Maehara Y; Kohashi K; Tsuneyoshi M; Taguchi T
Pediatr Transplant; 2007 Sep; 11(6):671-5. PubMed ID: 17663692
[TBL] [Abstract][Full Text] [Related]
3. Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab.
Svoboda J; Kotloff R; Tsai DE
Transpl Int; 2006 Apr; 19(4):259-69. PubMed ID: 16573540
[TBL] [Abstract][Full Text] [Related]
4. Post-transplant lymphoproliferative disorders in liver transplanted patients: a single-centre experience.
Marino D; Burra P; Boccagni P; Calabrese F; Canova F; Trentin C; Boso C; Soldà C; Angeli P; Aversa SM
Anticancer Res; 2010 Jun; 30(6):2383-91. PubMed ID: 20651397
[TBL] [Abstract][Full Text] [Related]
5. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
Trappe R; Riess H; Babel N; Hummel M; Lehmkuhl H; Jonas S; Anagnostopoulos I; Papp-Vary M; Reinke P; Hetzer R; Dörken B; Oertel S
Transplantation; 2007 Apr; 83(7):912-8. PubMed ID: 17460562
[TBL] [Abstract][Full Text] [Related]
6. Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment.
Garcia VD; Bonamigo Filho JL; Neumann J; Fogliatto L; Geiger AM; Garcia CD; Barros V; Keitel E; Bittar AE; Ferrera des Santos A; Roithmann S
Transpl Int; 2003 Mar; 16(3):202-6. PubMed ID: 12664217
[TBL] [Abstract][Full Text] [Related]
7. Post-transplant lymphoproliferative disorders after lung transplantation: first-line treatment with rituximab may induce complete remission.
Knoop C; Kentos A; Remmelink M; Garbar C; Goldman S; Feremans W; Estenne M
Clin Transplant; 2006; 20(2):179-87. PubMed ID: 16640524
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus polymerase chain reaction-negative stage IV post-transplant lymphoproliferative disorder in a heart transplant patient treated with rituximab.
Garceau P; Couture C; Cantin B; Bernier V; Sénéchal M
J Heart Lung Transplant; 2008 Aug; 27(8):928-31. PubMed ID: 18656811
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of EBV PTLD with CNS lymphomas with the monoclonal anti-CD20 antibody rituximab.
Kordelas L; Trenschel R; Koldehoff M; Elmaagacli A; Beelen DW
Onkologie; 2008 Dec; 31(12):691-3. PubMed ID: 19060508
[TBL] [Abstract][Full Text] [Related]
10. [Epstein-Barr virus-associated post-transplant lymphoproliferative disorder diagnosed by the episode of intestinal perforation following allogeneic hematopoietic stem cell transplantation].
Aimoto M; Yamane T; Inoue A; Momose D; Moriguchi-Aimoto R; Wada-Inoue E; Okamoto S; Koh H; Nakane T; Takeoka Y; Akahori-Nakamae M; Nishiki-Kosaka S; Terada Y; Nakamae H; Koh KR; Nakao T; Ohsawa M; Hino M
Rinsho Ketsueki; 2010 Dec; 51(12):1775-80. PubMed ID: 21258188
[TBL] [Abstract][Full Text] [Related]
11. Role of chemotherapy and rituximab for treatment of posttransplant lymphoproliferative disorder in solid organ transplantation.
Lee JJ; Lam MS; Rosenberg A
Ann Pharmacother; 2007 Oct; 41(10):1648-59. PubMed ID: 17848421
[TBL] [Abstract][Full Text] [Related]
12. Occurrence of post-transplant lymphoproliferative disorders among over thousand adult recipients: any role for hepatitis C infection?
Burra P; Buda A; Livi U; Rigotti P; Zanus G; Calabrese F; Caforio A; Menin C; Canova D; Farinati F; Luciana Aversa SM
Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1065-70. PubMed ID: 16957512
[TBL] [Abstract][Full Text] [Related]
13. Aggressive posttransplant lymphoproliferative disease in a renal transplant patient treated with alemtuzumab.
Muzaffar M; Taj A; Ratnam S
Am J Ther; 2010; 17(6):e230-3. PubMed ID: 19918163
[TBL] [Abstract][Full Text] [Related]
14. Post-transplantation lymphoproliferative disorders localizing to the gastrointestinal tract after liver transplantation: report of five pediatric cases.
Lai YC; Ni YH; Jou ST; Ho MC; Wu JF; Chen HL; Hu RH; Jeng YM; Chang MH; Lee PH
Pediatr Transplant; 2006 May; 10(3):390-4. PubMed ID: 16677368
[TBL] [Abstract][Full Text] [Related]
15. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease.
González-Barca E; Domingo-Domenech E; Capote FJ; Gómez-Codina J; Salar A; Bailen A; Ribera JM; López A; Briones J; Muñoz A; Encuentra M; de Sevilla AF; ; ;
Haematologica; 2007 Nov; 92(11):1489-94. PubMed ID: 18024397
[TBL] [Abstract][Full Text] [Related]
16. Long-term survival after post-transplant lymphoproliferative disease in children.
Nathanson S; Debray D; Delarue A; Deschênes G
Pediatr Nephrol; 2002 Aug; 17(8):668-72. PubMed ID: 12185479
[TBL] [Abstract][Full Text] [Related]
17. Post-transplant lymphoproliferative disorder treated with rituximab: case report.
Meng HT; Li Y; Liu JH; Xu GX; Teng XD
Chin Med J (Engl); 2007 May; 120(9):841-3. PubMed ID: 17531130
[No Abstract] [Full Text] [Related]
18. Poor outcome in post transplant lymphoproliferative disorder with pulmonary involvement after allogeneic hematopoietic SCT: 13 years' experience in a single institute.
Hou HA; Yao M; Tang JL; Chen YK; Ko BS; Huang SY; Tien HF; Chang HH; Lu MY; Lin TT; Lin KH; Hsiao CH; Lin CW; Chen YC
Bone Marrow Transplant; 2009 Feb; 43(4):315-21. PubMed ID: 18836488
[TBL] [Abstract][Full Text] [Related]
19. Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder.
Ganne V; Siddiqi N; Kamaplath B; Chang CC; Cohen EP; Bresnahan BA; Hariharan S
Clin Transplant; 2003 Oct; 17(5):417-22. PubMed ID: 14703923
[TBL] [Abstract][Full Text] [Related]
20. A case of post-transplant lymphoproliferative disease presenting as CD20-expressing, Epstein-Barr-virus positive Hodgkin lymphoma.
Stern M; Herrmann R; Rochlitz C; Dirnhofer S; Pless M
Eur J Haematol; 2005 Mar; 74(3):267-70. PubMed ID: 15693799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]